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Correlates of Metabolic Abnormalities in Bipolar 
I Disorder at Initiation of Acute Phase Treatment 
 
 
 
ObjectiveaaTreatment of bipolar patients is often complicated by metabolic abnormalities 
such as obesity, diabetes, and dyslipidemia. We therefore evaluated the prevalence of these 
abnormalities and their correlates, in bipolar I patients, at the time of commencement of phar-
macological treatment for acute mood episodes. 
MethodsaaThe study cohort consisted of 184 bipolar I patients hospitalized for treatment of 
acute mood episodes. Socio-demographic and clinical variables were noted and metabolic 
parameters, including body mass index, fasting plasma glucose, fasting total cholesterol, 
and current treatment(s) for diabetes and/or dyslipidemia were measured before initiating 
medication(s). 
ResultsaaFifty-six (30.4%) subjects met our criteria for obesity; 80 (43.5%) had hypergly-
cemia, with 8 (4.3%) receiving anti-diabetic medication; and 38 (20.7%) had hypercholes-
terolemia, with 2 (1.1%) receiving cholesterol-lowering agents. We found that male sex (χ2= 
5.359, p=0.021), depressed or mixed state versus manic state (χ2=4.302, p=0.038), and dura-
tion of illness (t=2.756, p=0.006) were significantly associated with obesity. Older age (t= 
3.668, p<0.001), later age of disease onset (t=2.271, p=0.024), and lower level of educa-
tional attainment (β=-0.531, p=0.001) were associated with hyperglycemia. 
ConclusionaaOur finding that metabolic abnormalities are prevalent when initiating acute 
pharmacological treatment in bipolar I patients indicates that these factors should be inte-
grated into treatment plans at the onset of disease management. 
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Introduction 
 
Treatment of patients with bipolar disorder is often complicated by metabolic ab-
normalities including obesity, diabetes, and dyslipidemia. The prevalence of obesity
in patients with bipolar disorder has been reported to range from 20% to 35%, signi-
ficantly higher than in the general population.
1-5 In addition, the prevalence of type II
diabetes mellitus in patients with bipolar I disorder has been reported to range from
10% to 26%, as much as threefold higher than matched estimates in the general pop-
ulation.
6-8 Moreover, abnormalities in cholesterol and fatty acid metabolism may be
associated with bipolar disorders.
9-11 Furthermore, 30% to 49% of bipolar patients 
have been found to meet the criteria for metabolic syndrome, which is characterized
by dysfunctions in glucose and lipid metabolism.
12,13 
The burden of metabolic syndrome is not limited to medical problems, such as type
2 diabetes mellitus, cardiovascular disease, and stroke,
14-16 but can also affect mental 
illness presentation, course, and response to treatment. For example, obesity in bipo-
lar patients has been correlated with a greater number of lifetime depressive and man-
ic episodes and a greater risk of developing an affective recurrence.
4 Recent work has 
shown that bipolar patients with diabetes mellitus had a greater number of lifetime psy- 
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chiatric hospitalizations than did non-diabetic bipolar pa-
tients.
17 Bipolar patients who met the criteria for metabol-
ic syndrome were more likely to report a lifetime history 
of suicide attempts than those without the metabolic syn-
drome.
12 Thus, preventing metabolic dysregulation might 
not only decrease medical illness and mortality in bipolar 
patients, but may also improve course of illness in bipo-
lar disorder. 
Decisions regarding pharmacological treatment are in-
creasingly influenced by concerns regarding metabolic 
risks associated with individual medications. For example, 
treatment with atypical antipsychotics has been associ-
ated with clinically significant weight gain and obesity, as 
well as with hyperglycemia, exacerbation of pre-existing 
diabetes or development of type 2 diabetes.
18 Polyphar-
macy is a common practice in bipolar disorder. Further-
more, combinations of atypical antipsychotics and mood 
stabilizers may result in additional risk for obesity and 
associated metabolic abnormalities in bipolar patients.
19 
The hazards posed by metabolic abnormalities as well as 
the risk for further disruption of metabolic parameters with 
psychiatric medication invites the need for a priori consid-
eration of metabolic issues in all bipolar patients.   
The baseline pretreatment prevalence of metabolic ab-
normalities holds promise to improve patient outcome vis- 
à-vis risk stratification and appropriate medication assign-
ment. Hitherto, most studies documenting metabolic pro-
files in bipolar patients have most often included individ-
uals who have received complex pharmacological regimens 
prior to evaluation. In this study we extend knowledge re-
garding metabolic abnormalities in bipolar individuals by 
reporting on the prevalence of obesity, hyperglycemia, and 
hypercholesterolemia, and their clinical correlates, in bi-
polar I patients prior to the initiation of pharmacological 
treatment for an acute mood episode. 
 
Methods 
 
The study cohort consisted of 184 bipolar I patients 
hospitalized at a university hospital in Seoul, Korea, for 
treatment of acute mood episodes between January 2005 
and December 2006. Subjects were between 19 and 64 
years of age. All patients were diagnosed according to the 
criteria of the Diagnostic and Statistical Manual of Men-
tal Disorders, fourth edition (DSM-IV) by two or more ex-
perienced psychiatrists. For patients admitted more than 
once during the study period, data from the index admis-
sion were used. The institutional review board of the Asan 
Medical Center, Ethics Committee, approved this study, 
and waived the requirement for informed consent because 
measurements of weight and height and assessments adapt-
ed in this study were part of routine clinical practice. 
Socio-demographic and clinical variables were collect-
ed, and metabolic parameters, including body mass index 
(BMI), fasting plasma glucose (FPG), and fasting total 
cholesterol, were measured before initiating medication 
(s). Current treatment(s) for diabetes and/or dyslipidemia 
was confirmed by review of each patient’s medical records. 
Physical data included body weight and height, with BMI 
calculated as weight in kilograms divided by height in me-
ters squared. Obesity was defined according to the crite-
rion and classification in Japan and Asia-Oceania,
20 as 
BMI over 25 kg/m
2. This criterion is considered appropri-
ate for Asians whose main energy intake comes from car-
bohydrates, and has been adapted for Koreans. Biochemi-
cal parameters were checked on the morning of the day 
following admission, with the patient in the fasting state. 
Hyperglycemia was defined as FPG ≥110 mg/dL and hy-
percholesterolemia as ≥200 mg/dL.   
To assess the correlation of obesity, hyperglycemia, and 
hypercholesterolemia with socio-demographic and clini-
cal factors, we recorded patient age, sex, marital status, 
years of education, occupation, socioeconomic status, age 
at onset of illness, duration of illness, number of previous 
hospitalizations, and history of previous psychiatric med-
ications. Socio-demographic and clinical variables are re-
ported as means and standard deviations for continuous 
variables and frequency/percentage for non-continuous 
variables. Chi-square or Fisher’s exact tests for sex, mood 
state, history of psychotropic medications, occupation, so-
cio-economic status and marital status were used to assess 
differences between two groups (obese vs. non-obese; hy-
perglycemic vs. normal FPG; hypercholesterolemic vs. 
normal cholesterol). Continuous variables, including age, 
age of disease onset, duration of illness, and number of 
previous hospitalizations, were compared using Student’s 
t-test. Logistic regression analysis, using the two potential 
correlates as independent variables, was used to determine 
if there were significant correlations between educational 
levels and the presence or absence of metabolic abnormal-
ities. All statistical analyses were performed with Statis-
tical Package for Social Science (SPSS) version 12.0 for 
Windows, with statistical significance defined as p<0.05. 
 
Results 
 
The socio-demographic and clinical characteristics of 
study subjects are presented in Table 1. The mean patient 
age was 38.0±13.2 years, and 96 (52.2%) were female. 
The mean age of disease onset was 30.8±11.7 years and 
the mean duration of illness was 8.2±8.4 years. Of the 184 
subjects, 128 (69.6%) were manic, 48 (26.1%) were depre-
ssed, and 8 (4.3%) were mixed at the time of hospitaliza-
tion. Prior medications used before the index hospitaliza- 
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tions are listed in Table 2. Although most patients were 
taking more than one medication, 70 (38.0%) had never 
been prescribed psychotropic medications. The most fre-
quently prescribed antipsychotics were olanzapine (26.1%) 
and risperidone (25.5%), whereas the most frequently pre-
scribed mood stabilizers were lithium (31.0%) and dival-
proex (29.9%).  
We found that 56 (30.4%) bipolar patients met the Asian 
criterion for obesity (BMI ≥25 kg/m
2)(Table 3); 80 (43.5%) 
had hyperglycemia (FPG ≥110 mg/dL), with 8 (4.3%) tak-
ing anti-diabetic agents; and 38 (20.7%) had hypercholes-
terolemia (≥200 mg/dL), with 2 (1.1%) on cholesterol-low-
ering agents (Table 2). There was a significant difference 
in the prevalence of obesity between male and female sub-
jects (χ2=5.359, p=0.021), but no other significant differ-
ences related to sex (Table 3).  
Table 4 shows comparisons of socio-demographic and 
clinical characteristics between groups sorted according 
to the presence of each metabolic variable. When we com-
pared obese and non-obese subjects, we found that male 
sex (χ2=5.359, p=0.021), episode polarity, i.e. depressed 
or mixed rather than manic state (χ2=4.302, p=0.038), and 
duration of illness (t=2.756, p=0.006) were significantly 
associated with obesity. Although the level of education 
did not differ significantly in obese and non-obese sub-
jects, less-educated subjects tended to have a higher pre-
valence of obesity (p=0.054). Older age (t=3.668, p<0.001), 
later age of disease onset (t=2.271, p=0.024), and lower 
level of education (β=-0.531, p=0.001) were significantly 
associated with hyperglycemia. We found no statistically 
significant variable associated with hypercholesterolemia 
(data not shown). When we sorted groups according to his-
TABLE 1. Socio-demographic and clinical characteristics of bipo-
lar I patients (N=184) at initiating acute phase treatment (%) 
Age (years; mean±SD) 38.0±13.2 
Sex (female number)  096 (52.2) 
Mood state (N)  
Manic 128  (69.6) 
Depressive  048 (26.1) 
Mixed  008 (04.3) 
Age of onset (years; mean±SD) 30.8±11.7 
Duration of illness (years; mean±SD)  08.2±08.4 
Number of previous hospitalization   
(number; mean±SD) 
02.2±02.8 
Occupation (N, %)  
With a regular occupation  103 (56.0) 
Without a regular occupation  081 (44.0) 
Level of education (N, %)  
0-6 years  015 (08.2) 
7-9 years  010 (05.4) 
10-12 years  052 (28.3) 
13-16 years  095 (51.6) 
More than 16 years  012 (06.5) 
Socio-economic status (N, %)  
High  053 (28.8) 
Middle  098 (53.3) 
Low  033 (17.9) 
Marital status (N, %)  
Unmarried  063 (34.2) 
Married 108  (58.7) 
Separated or divorced  013 (07.1) 
 
TABLE 2. Psychotropic medications used before entering acute 
phase treatment 
 N  (%) 
Antipsychotics  
Olanzapine 48  (26.1) 
Risperidone 47  (25.5) 
Quetiapine 29  (15.8) 
Aripiprazole  08 (04.3) 
Haloperidol  07 (03.8) 
Amilsupiride  06 (03.3) 
Ziprasidone  03 (01.6) 
Clozapine  01 (00.5) 
Mood stabilizers   
Lithium 57  (31.0) 
Divalproex 55  (29.9) 
Carbamazepine 11  (06.0) 
Lamotrigine 18  (09.8) 
Antidepressants  
SSRI 42  (22.8) 
Bupropion 14  (07.6) 
Mirtazapine 13  (07.1) 
No prescribed psychotropic medications  70 (38.0) 
If more than 2 medications had been used in a patient, each 
medication was counted separately. SSRI: selective serotonin re-
uptake inhibitor 
 
TABLE 3. Prevalence of metabolic abnormalities in bipolar I patients
Metabolic parameters  Total (N=184)(%) Female  (N=96)(%) Male  (N=88)(%) 
Obesity (BMI ≥25) 56  (30.4) 22  (22.9) 34  (38.6) 
Hyperglycemia (fasting plasma glucose ≥110) 80  (43.5) 37  (38.5) 43  (48.9) 
Taking anti-diabetic medication  08 (04.3)  03 (01.6)  05 (02.7) 
Hypercholesterolemia (cholesterol ≥200) 38  (20.7) 22  (22.9) 16  (18.2) 
Taking cholesterol-lowering agent  02 (01.1)  01 (00.5)  01 (00.5) 
BMI: body mass index    
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tory of usage of psychotropic medications (i.e. antipsy-
chotics, mood stabilizers, and antidepressants), we found 
no significant differences in the frequencies of abnormal-
ities in metabolic parameters (Table 5).  
Of the variables investigated, multiple logistic regres-
sion analysis showed that sex (p=0.007) and episode po-
larity (p=0.011) were independently associated with obe-
sity, and that age (p=0.005) and educational level (p= 
0.012) were independently associated with the presence 
of hyperglycemia or anti-diabetic medication usage. 
 
Discussion 
 
Our analysis indicates that disparate metabolic varia-
bles e.g. obesity, hyperglycemia, and hypercholesterole-
mia, were highly prevalent in a large sample of patients 
(n=184) with bipolar I disorder at the time of hospitaliz-
ation. As the prevalence of metabolic problems is signi-
ficantly higher in bipolar patients than in the general pop-
ulation, pharmacologic treatment should be implemented 
only after consideration of metabolic risk factors. In par-
ticular, bipolar patients beginning pharmacological treat-
ment for acute mood episodes may be more vulnerable to 
metabolic derangements, because significant weight gain 
has been shown to occur during acute treatment with atyp-
ical antipsychotics in combination with mood stabilizers.
19 
Therefore, it is clinically important to determine whether 
metabolic risks are present at the initiation of acute treat-
TABLE 4. Correlates of metabolic abnormalities in bipolar I patients
 BMI  ≥25 BMI  <25  p  FPG≥110 or anti-diabetic medication  FPG <110  p 
Age (years) 39.8±13.3 37.3±13.2  0.24  42.0±12.8 35.0±12.8  <0.01 
Sex (N)(%)     0.02     <0.16 
Female 22  (22.9) 74  (77.1)   37  (38.5) 59  (61.5)  
Male 34  (38.6) 54  (61.4)   43  (48.9) 45  (51.1)  
Mood state (N)(%)     0.04     <0.28 
Manic 33  (25.8) 95  (74.2)   59  (46.1) 69  (53.9)  
Depressive or mixed  23 (41.1) 33  (58.9)   21  (37.5) 35  (62.5)  
Age of onset (years) 30.1±11.4 31.2±11.9  0.59  33.1±11.8 29.2±11.5  <0.02 
Duration of illness (years)* 10.7±09.7  07.2±07.5  0.01  10.0±09.7  06.9±07.0  <0.10 
Previous hospitalization (number)  02.6±02.9  02.0±02.7  0.26  02.2±02.7  02.2±02.8  <0.91 
Occupation (N)(%)     0.83     <0.08 
Yes 32  (31.1) 71  (68.9)   39  (37.9) 64  (62.1)  
No 24  (29.6) 57  (70.4)   41  (50.6) 40  (49.4)  
Level of education (N)(%)     0.05     <0.01 
0-6 years  08 (53.3)  07 (46.7)   10  (66.7)  05 (33.3)  
7-9 years  04 (40.0)  06 (60.0)   09 (90.0)  01 (10.0)  
10-12 year  16 (30.8) 36  (69.2)   25  (48.1) 27  (51.9)  
13-16 years  24 (25.3) 71  (74.7)   31  (32.6) 64  (67.4)  
More than 16 years  04 (33.3)  08 (66.7)   05 (41.7)  07 (58.3)  
Socio-economic status (N)(%)     0.78     <0.14 
High 15  (28.3) 38  (71.7)   17  (32.1) 36  (67.9)  
Middle 32  (32.7) 66  (67.3)   47  (48.0) 51  (52.0)  
Low  09 (27.3) 24  (72.7)   16  (48.5) 17  (51.5)  
Marital status (N)(%)     0.35     <0.09 
Unmarried 15  (23.8) 48  (76.2)   23  (36.5) 40  (63.5)  
Married 36  (33.3) 72  (66.7)   48  (44.4) 60  (55.6)  
Separated or divorced  05 (38.5)  08 (61.5)   09 (69.2)  04 (30.8)  
*t-test after log transformation. BMI: body mass index, FPG: fasting plasma glucose 
 
TABLE 5. Comparison of patients who have taken psychotropic medication(s) before entering acute treatment and those who have not
Previous 
psychotropic 
medications (N) 
BMI  
≥25 
BMI  
<25 
Statistics p 
FPG ≥110 or  
anti-diabetic 
medication 
FPG   
<110 
Statistics  p 
Cholesterol≥200 
or cholesterol- 
lowering agent 
Cholesterol 
<200 
Statistics  p 
Yes (N=114)  40  74 (64.9)     48  (42.1) 66  (57.9)    25  (21.9) 89  (78.1)    
No (N=70)  16 
( )
54 (77.1)  χ2=3.064 0.080  32  (45.7) 38  (54.3)  χ2=0.230  0.632  13 (18.6) 57  (81.4)  χ2=0.299 0.585 
BMI: body mass index, FPG: fasting plasma glucose 
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ment, as well as to measure the clinical and socio-demo-
graphic variables associated with metabolic risks in bi-
polar patients.   
Our findings need to be considered in the context of ex-
tant data. For example, epidemiological and clinical stud-
ies indicate that the prevalence of obesity in bipolar indi-
viduals is approximately 20% to 35%.
1-5 Our observation 
that 30.4% of patients in this cohort were obese at the start 
of treatment is in line with previous reports. We observed 
significant associations between obesity and male sex, 
episode polarity i.e. depressed or mixed, and longer dura-
tion of illness. Multiple logistic regression analysis showed 
that male sex and depressive or mixed state were signifi-
cant independent factors associated with obesity. These 
correlations are consistent with results reporting that male 
sex
21 and depressive symptoms
3,4 were related to obesity 
in bipolar patients. In addition, years of education, eco-
nomic status, and ethnicity have been found to be associ-
ated with obesity.
4,21 Although we found that the preva-
lence of obesity tended to be higher in subjects with a low-
er level of education, this association was not statistically 
significant.  
The overall prevalence of hyperglycemia in our study 
cohort was significantly elevated at 43.5%. Data from 
studies evaluating metabolic syndrome in Caucasian pa-
tients with bipolar disorder reported a prevalence of hy-
perglycemia (i.e. FPG ≥110 mg/dL), ranging from 8.0% 
to 16.9%.
12,22-25 As FPG >110 mg/dL has been reported to 
be the most specific factor (95.2%) in correctly identify-
ing the presence of metabolic syndrome,
26 the high pro-
portion of our patients with elevated FPG is note worthy. 
Heterogeneity in study outcomes regarding hyperglyce-
mia may be due to differences between studies in sample 
composition, definitions of hyperglycemia, and sampling 
procedures. For example, some Asian populations are dif-
ferentially affected by insulin resistance and diabetes mel-
litus.
27,28 Although we did not measure cortisol concentra-
tions, hyper-cortisolemia may be associated with hyper-
glycemia, as acute mood symptoms may be preceded and 
accompanied by increases in adrenocorticotropic hormone 
levels. The disturbances in cortisol regulation seen in bi-
polar disorder play a role in the development of core man-
ifestations of metabolic syndrome, such as insulin resis-
tance, hyperglycemia, obesity, and dyslipidemia.
29 
Subjects presenting with hyperglycemia or taking anti- 
diabetic medications were significantly older (42.0±12.8 
years) than those without hyperglycemia (35.0±12.8 years). 
Aging is accompanied by a loss of muscle mass and by 
an increase in body fat, which may lead to increased insu-
lin resistance and subsequent metabolic syndrome.
30 More-
over, diabetic bipolar patients have been reported to be 
significantly older than non-diabetic bipolar patients.
13,17,31 
The prevalence of hyperglycemia was significantly asso-
ciated with a lower level of education in bipolar patients. 
Although we could not determine a causal relationship be-
tween education and hyperglycemia, an unhealthy life style, 
including increased intake of carbohydrates and sweets, 
may be contributory.   
We also found that 20.7% of our subjects had increas-
ed total cholesterol levels (≥200 mg/dL). To our knowl-
edge, there have been no studies specifically addressing 
the frequency of abnormal cholesterol levels in bipolar 
patients at the time of acute mood episodes. Combined 
with the high frequency of obesity and hyperglycemia, our 
finding that 20% of patients had hypercholesterolemia 
warrants the need for attention when treating bipolar pa-
tients with medications that can disrupt metabolic para-
meters.  
As atypical antipsychotics have been reported to be as-
sociated with a high prevalence of metabolic abnormal-
ities,
32,33 bipolar patients prescribed these medications 
are more likely to exhibit a greater frequency of metabol-
ic disturbances, including obesity, hyperglycemia, and 
hypercholesterolemia. However, we did not observe a sig-
nificant association between the uses of psychotropic med-
ications before entering acute phase treatment with inter-
ferences in these parameters. Additionally, subgroup anal-
yses of patients treated with some atypical antipsychotics, 
i.e. olanzapine, risperidone, and quetiapine, did not reveal 
an independent association between use of these medi-
cations and obesity, hyperglycemia, or hypercholesterol-
emia (data not shown). These unexpected results may in 
part be due to limitations in adherence to medication. In 
particular, bipolar patients exhibit high rates of nonadher-
ence with prescribed treatments both pharmacological and 
psychosocial. In addition, because the effects of medica-
tion may compound inherent risk factors for metabolic syn-
drome, the effects of medication cannot fully account for 
the myriad metabolic abnormalities observed in our pa-
tients. 
Our study had several methodological limitations. First, 
we did not collect detailed information on health habits, 
such as smoking, use of drugs and alcohol, excessive ca-
loric and cholesterol intake, and physical inactivity, all of 
which may contribute to the metabolic abnormalities ob-
served. A second limitation was the cross-sectional design 
of our study which precludes us from establishing causal 
relationships among variables. Third, our sample was re-
latively small (n=184) and derived from a single univer-
sity hospital which may not be representative of outpatients 
with bipolar disorder and/or other individuals with less 
complex illness presentations. A fourth limitation is that 
our study did not include other metabolic parameters, such 
as levels of triglyceride and low-and high-density lipopro- 
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tein cholesterol, which are important constituents of met-
abolic syndrome. Lastly, we did not control for baseline 
indices of illness severity or length of psychotropic drug 
treatment. In addition, our subjects consisted of drug-na-
ïve patients and those who have taken psychotropic medi-
cations before enrolling this study, which could affect the 
results of our study. The finding that there was no signif-
icant association between the uses of psychotropic med-
ications before entering acute phase treatment and the in-
terferences of metabolic parameters should be interpreted 
by considering this particular methodological limitation. 
In summary, metabolic abnormalities are prevalent in 
bipolar individuals at the time of initiating pharmacolo-
gical treatment for an acute episode requiring hospitaliza-
tion. The high prevalence of metabolic abnormalities as 
well as the hazards posed by their occurrence invites the 
need for practitioners to carefully screen all bipolar pa-
tients for risk factors related to metabolic abnormalities 
as well as careful clinical surveillance for incident distur-
bances in any metabolic parameter. The selection and se-
quencing of psychotropic agents in managing bipolar pa-
tients needs to be informed by possible metabolic disrup-
tion. The incorporation of psychosocial treatment strategies 
that emphasize educational aspects related to metabolic 
risk and medical comorbidity holds promise to reduce the 
burden of illness and improve outcomes in bipolar disorder. 
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